Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Beeline raises $300m for BMS drugs, and other biofinancings

 April 16, 2026

Pharmaphorum

Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.

M&A / DealsRead full story

Post navigation

Most patients “won’t see benefit” with Alzheimer’s drugs →
← Revolution doubles stock offering target to $2B following pancreatic cancer win

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com